DIVISLAB2020-04-012020-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member DIVISLAB2020-04-012020-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss02Member DIVISLAB2020-04-012020-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss03Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares DIVISLAB 2020-04-01 2021-03-31 2020-07-29 INR Lakhs First quarter Single segment Pharmaceuticals 2020-04-01 2020-06-30 Unaudited Standalone 17099600000.00 178700000.00 17278300000.00 4594900000.00 0.00 1771900000.00 1803500000.00 1800000.00 559700000.00 1939500000.00 10671300000.00 6607000000.00 0.00 6607000000.00 1864800000.00 -180300000.00 1684500000.00 0.00 4922500000.00 0.00 0.00 0.00 4922500000.00 -2500000.00 4920000000.00 530900000.00 2 18.54 18.54 0.00 0.00 18.54 18.54 1. The above Financial Results for the quarter ended 30th June, 2020 (Statement) is prepared in accordance with Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI ( LODR) Regulations, 2015. The Statement is, as reviewed by the Audit Committee, considered and approved by the Board of Directors at its meeting held on 8th August,2020. The Statement is subjected to ¿limited review¿ by the Auditors of the Company and their report contains no qualification.2.The Company is engaged in the manufacture of Active Pharmaceutical Ingredients, Intermediates and Nutraceutical Ingredients; and the same constitutes a single reporting business segment as per Ind AS108. 3.The Company does not have any discontinued operations and the Profit for the period represents Profits from continuing operations only.4. The Company has not experienced any significant impact on its operations, supply chain and recoverability of carrying amounts of financial and non-financial assets due to COVID 19 pandemic. As the pandemic continues to evolve, the Company will continue to closely monitor for any material changes to future economic conditions.5.Current Tax Expense includes adjustment of tax reversals of earlier years amounting to Rs.665 lakhs.6.Forex gain included in Other Income / (loss) included in Other Expenses for the respective periods is as given below (Rs.in lakhs):Forex gain /(loss) -Quarter Ended -30.06.2020-Rs.535, 31.03.2020-Rs.5716,30.06.2019-Rs.(596),Year Ended-31.03.2020-Rs.8204.7. *Figures for the quarter ended 31.03.2020 are the balancing figures between audited figures in respect of full financial year and the unaudited published year to date figures up to the third quarter of the respective financial year.8.Figures for the previous year/period are regrouped or reclassified wherever necessary to conform to current periods classification.